Incyte Corp v. Alembic Pharma Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Incyte Corporation and Incyte Holdings Corporation (Delaware)
  • Defendant: Alembic Pharmaceuticals Limited (India) and Alembic Pharmaceuticals, Inc. (New Jersey)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 1:26-cv-07841, D.N.J., 06/26/2026
• Venue Allegations: Venue is asserted based on Defendant Alembic Pharmaceuticals, Inc. having a principal place of business in the District of New Jersey, and Defendant Alembic Pharmaceuticals Limited being a foreign corporation.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the drug Jakafi® (ruxolitinib) constitutes an act of infringement of six patents covering the active pharmaceutical ingredient, its salts, and methods of use.
• Technical Context: The technology relates to small molecule inhibitors of Janus kinases (JAKs), a family of enzymes integral to cell signaling pathways, particularly those involved in the immune system and cell growth.
• Key Procedural History: This is a Hatch-Waxman action triggered by Defendants' submission of ANDA No. 221546 seeking to market a generic version of Jakafi® prior to the expiration of Plaintiff's patents. Defendants filed a Paragraph IV certification, asserting that the patents-in-suit are invalid and/or will not be infringed by their proposed product. The complaint notes that the matter is related to other pending litigation involving the same patents against different generic drug manufacturers.

Case Timeline

Date	Event
2006-01-13	Priority Date for '257 and '362 Patents
2007-06-13	Priority Date for '693, '481, '013, and '429 Patents
2009-10-06	'257 Patent Issued
2013-04-09	'362 Patent Issued
2014-05-13	'693 Patent Issued
2014-09-02	'481 Patent Issued
2014-09-09	'013 Patent Issued
2018-07-10	'429 Patent Issued
2026-06-26	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,598,257 - "Heteroaryl Substituted Pyrrolo[2,3-b]pyrimidines and Pyrrolo[2,3-b]pyridines as Janus Kinase Inhibitors"

The Invention Explained

• Problem Addressed: The patent describes a need for compounds that can modulate the activity of protein kinases, which are a large family of enzymes that regulate diverse and important biological processes ʻ257 Patent, col. 4:7-13 Specifically, it identifies the Janus kinase (JAK) family as a key target for treating diseases related to abnormal cellular responses triggered by cytokine signaling, such as immune-related diseases, myeloproliferative disorders, and cancer ʻ257 Patent, col. 6:15-23
• The Patented Solution: The invention provides a class of chemical compounds, generally described as heteroaryl-substituted pyrrolo[2,3-b]pyrimidines and pyrrolo[2,3-b]pyridines, that are asserted to be useful as inhibitors of JAKs ʻ257 Patent, abstract ʻ257 Patent, col. 6:24-34 These compounds are defined by a core chemical structure (Formula I) with various specified substituent groups.
• Technical Importance: This technology provided a novel chemical scaffold for creating potent inhibitors of the JAK family, a class of therapeutic targets that was gaining significance for treating a range of inflammatory and oncologic conditions.

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" of the '257 Patent without specifying which ones Compl. ¶37 Independent claim 1 is a composition of matter claim covering a broad genus of compounds.
• Claim 1 of the '257 patent claims:
  • A compound of Formula I, which depicts a core pyrrolo[2,3-d]pyrimidine structure.
  • Or a pharmaceutically acceptable salt or a prodrug thereof.
  • The claim further defines the various chemical groups (A1, A2, U, V, X, Y, Z, and numerous R groups) that can be attached to the core structure, creating a large Markush group of related compounds.

U.S. Patent No. 8,415,362 - "Pyrazolyl Substituted Pyrrolo[2,3-b]pyrimidines as Janus Kinase Inhibitors"

The Invention Explained

• Problem Addressed: Similar to the '257 patent, this patent addresses the need for effective modulators of JAK enzymes to treat diseases associated with their activity, including immune disorders and cancer ʻ362 Patent, col. 6:25-34
• The Patented Solution: The patent claims a class of pyrazolyl-substituted pyrrolo[2,3-b]pyrimidine compounds, including the specific compound 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, also known as ruxolitinib ʻ362 Patent, abstract ʻ362 Patent, col. 414:20-25 These compounds are presented as inhibitors of JAKs.
• Technical Importance: This patent specifically identifies and claims the chemical structure for ruxolitinib, the active ingredient in the commercially successful drug Jakafi®, representing a significant development in the field of JAK inhibitors.

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" of the '362 patent Compl. ¶46 Independent claim 1 is a broad composition of matter claim, and claim 21 specifically claims the compound that is ruxolitinib.
• Claim 1 of the '362 patent claims:
  • A compound of Formula I, a pyrazolyl substituted pyrrolo[2,3-b]pyrimidine.
  • Or a pharmaceutically acceptable salt thereof.
  • The claim includes a complex Markush structure defining the possible substituents for the core molecule. A Certificate of Correction was issued for this patent, correcting numerous chemical terms within the claims, a detail that may be relevant to claim construction.

U.S. Patent No. 8,722,693 - "Salts of the Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile"

Technology Synopsis

This patent addresses the need for forms of the ruxolitinib compound with improved properties for formulation and administration, such as enhanced stability or solubility ʻ693 Patent, col. 2:25-31 It claims specific salt forms of ruxolitinib, namely the maleic acid, sulfuric acid, and phosphoric acid salts ʻ693 Patent, abstract

Asserted Claims

The complaint asserts infringement of "one or more claims" Compl. ¶55

Accused Features

The act of filing an ANDA for a generic drug product that is alleged to be or contain one of the claimed salt forms of ruxolitinib Compl. ¶55

U.S. Patent No. 8,822,481 - "Salts of the Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile"

Technology Synopsis

This patent, like the '693 patent, is directed to specific salt forms of ruxolitinib to provide advantageous pharmaceutical properties ʻ481 Patent, col. 2:25-31 It claims methods of modulating JAK activity by administering the phosphate salt of ruxolitinib, including in a crystalline form ʻ481 Patent, abstract '481 Patent, claim 1

Asserted Claims

The complaint asserts infringement of "one or more claims" Compl. ¶64

Accused Features

The proposed manufacture, use, or sale of a generic product containing the claimed phosphate salt of ruxolitinib for the purpose of modulating JAK activity Compl. ¶64

U.S. Patent No. 8,829,013 - "Salts of the Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile"

Technology Synopsis

This patent also covers salts of ruxolitinib ʻ013 Patent, col. 2:25-31 The claims are directed to methods of treating specific myeloproliferative disorders, such as polycythemia vera and essential thrombocythemia, by administering the phosphate salt of ruxolitinib ʻ013 Patent, claim 1 '013 Patent, claim 7

Asserted Claims

The complaint asserts infringement of "one or more claims" Compl. ¶73

Accused Features

The filing of an ANDA with a label that will allegedly instruct users to administer the generic ruxolitinib product for the treatment of the claimed disorders Compl. ¶33 Compl. ¶73

U.S. Patent No. 10,016,429 - "Salts of the Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-Pyrazol-1-yl)-3-Cyclopentylpropanenitrile"

Technology Synopsis

This patent covers specific methods of using a salt of ruxolitinib ʻ429 Patent, col. 2:26-32 The claims are specifically directed to a method of treating graft-versus-host disease in a patient in need thereof by administering a composition containing the phosphate salt of ruxolitinib ʻ429 Patent, claim 1

Asserted Claims

The complaint asserts infringement of "one or more claims" Compl. ¶82

Accused Features

The filing of an ANDA with a label that will allegedly instruct users to administer the generic ruxolitinib product for the treatment of graft-versus-host disease Compl. ¶33 Compl. ¶82

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Defendants' proposed generic ruxolitinib tablets in 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, for which Defendants seek FDA approval via ANDA No. 221546 ("Alembic's Proposed Products") Compl. ¶1 Compl. ¶22

Functionality and Market Context

The complaint alleges that Alembic's Proposed Products are generic versions of Incyte's Jakafi® drug product Compl. ¶1 As such, the active ingredient is ruxolitinib, a Janus kinase (JAK) inhibitor. The complaint alleges that the prescribing information for Alembic's Proposed Products will be similar to that for Jakafi® and will instruct physicians and patients to administer the product according to methods claimed in the patents-in-suit Compl. ¶16 Compl. ¶33 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide claim charts or detailed, element-by-element infringement allegations for any of the asserted patents. The infringement theory is a statutory one specific to Hatch-Waxman litigation under 35 U.S.C. § 271(e)(2)(A). The complaint alleges that the act of submitting ANDA No. 221546, which seeks FDA approval to market a generic version of Jakafi® before the expiration of the patents-in-suit listed in the Orange Book, constitutes an act of infringement Compl. ¶31 Compl. ¶37

• Identified Points of Contention:
  • Structural Identity: A primary question for the composition of matter patents ('257 and '362) will be whether the active pharmaceutical ingredient (API) in Alembic's Proposed Products is structurally identical to a compound falling within the scope of the claims. For a generic drug, this is often not disputed, but the focus shifts to the validity of the claims.
  • Salt Form and Polymorphism: For the patents claiming specific salts ('693, '481, '013, '429), a key point of contention may be whether the salt form and/or crystalline polymorph in Alembic's ANDA product is the same as the one claimed. Minor differences in crystalline structure could potentially be used to argue non-infringement.
  • Induced Infringement via Labeling: For the method-of-use patents ('481, '013, '429), the central dispute will likely be whether the proposed label for Alembic's product encourages, recommends, or promotes an infringing use. This will involve a detailed comparison of the language in the proposed label against the steps recited in the method claims Compl. ¶33
  • Validity: Defendants' Paragraph IV certification alleges that the patents are "invalid and/or will not be infringed" Compl. ¶35 Consequently, a major part of the litigation will likely involve Alembic challenging the validity of the asserted claims on grounds such as obviousness, lack of enablement, or anticipation.

V. Key Claim Terms for Construction

The complaint does not identify any specific claim terms for construction. However, based on the nature of chemical patents and Hatch-Waxman litigation, the following terms from the asserted independent claims may become focal points.

• The Term: "pharmaceutically acceptable salt" (from claim 1 of '257 and '362 patents)

• Context and Importance: This term's definition is fundamental to the scope of the composition of matter claims. Whether the specific salt form used by Alembic qualifies as "pharmaceutically acceptable" under the patents' definition could be a point of dispute, although such terms often have well-understood meanings in the art.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specifications provide a broad, exemplary list of acids and bases that can form such salts, stating the lists are not intended to be exhaustive, which may support a broad construction (e.g.,'257 Patent, col. 32:20-67).
  • Evidence for a Narrower Interpretation: A defendant could argue that the term should be limited by the examples provided in the patent or by what was known to be "acceptable" for this class of compounds at the time of invention.

• The Term: "crystalline salt" (from claim 1 of '481 patent)

• Context and Importance: This term is critical because pharmaceutical compounds can exist in various solid-state forms (polymorphs), some crystalline and some amorphous, with different physical properties. Infringement may depend on whether Alembic's product contains the specific crystalline form claimed.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification may describe methods for producing crystalline forms generally, which could support a construction covering any crystalline form produced by those methods.
  • Evidence for a Narrower Interpretation: The '693 patent provides specific characterization data for certain crystalline salts, such as X-ray powder diffraction (XRPD) peaks and differential scanning calorimetry (DSC) data (e.g.,'693 Patent, col. 11:5-11). A defendant may argue that "crystalline salt" is limited to forms exhibiting these specific characteristics.

VI. Other Allegations

• Indirect Infringement: Plaintiff alleges that Defendants will induce infringement of the method-of-use claims by providing a product with a label that instructs physicians and patients to use the generic drug for patented indications Compl. ¶40 Compl. ¶49 Compl. ¶58 Compl. ¶67 Compl. ¶76 Compl. ¶85 Plaintiff also alleges contributory infringement, stating that Alembic's proposed products are especially adapted for use in an infringing manner and lack substantial non-infringing uses Compl. ¶41 Compl. ¶50 Compl. ¶59 Compl. ¶68 Compl. ¶77 Compl. ¶86
• Willful Infringement: The complaint does not explicitly use the word "willful," but it alleges that Defendants have had and continue to have knowledge of the patents-in-suit Compl. ¶41 Compl. ¶50 This knowledge is allegedly based on the patents' listing in the FDA's Orange Book and the filing of the Paragraph IV certification Compl. ¶15 Compl. ¶34 Compl. ¶35 The complaint also asserts that this is an "exceptional case" entitling Incyte to attorneys' fees under 35 U.S.C. § 285 Compl. ¶44

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of claim scope versus product characteristics: Do the specific chemical composition, salt form, and crystalline structure of Alembic's proposed generic product fall within the literal scope of a valid claim in Incyte's patents, particularly the later patents that claim specific salts and crystalline forms?
• A second central question will be patent validity. Given the Paragraph IV certification, Alembic will almost certainly challenge the validity of the asserted patents. The key question for the court will be whether the inventions, from the broad genus claims of the '257 patent to the specific method-of-use claims of the '429 patent, meet the statutory requirements of novelty, non-obviousness, and written description.
• A third key question will revolve around induced infringement: Assuming the method-of-use claims are valid, does the language in the proposed label for Alembic's generic product actively encourage or instruct medical professionals to prescribe the drug for the specific disorders claimed in patents like '013 and '429, thereby creating liability for inducement?